1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)

Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)

  • May 2015
  • -
  • Roots Analysis Private Ltd.
  • -
  • 275 pages

INTRODUCTION
Given the intricacy of the anatomy and physiology of the eye, it is quite challenging to deliver an ophthalmic drug effectively to a specific ocular site. Several barriers have to be overcome for a successful ocular drug delivery. These include dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva and drug permeation issues with respect to the cornea, sclera and choroid. Approximately 95% of the drug, in topical eye drops, is lost due to the aforementioned barriers.

The widening gap between the demand of novel treatments and supply of drugs/ systems is going to provide a major impetus to the sustained release ocular drug delivery market in the coming decade. Different ocular drug delivery systems have been devised for supplying drugs effectively to various parts of the eye. Contact lenses and punctal plugs are used to deliver drugs to the anterior segment of the eye while intravitreal implants and injectable particulate systems are used for drug delivery into the posterior segment of the eye. There are both advantages and disadvantages of the existing drug delivery systems; advancements are being made to enhance ocular bioavailability and retention time of the drug.

In the past few years, these implants and inserts have become one of the key focus areas of researchers and companies alike. Several venture capital firms have backed the smaller organizations working in this field. In addition, partnerships and collaborations have played a pivotal role in the advancement of the market.

SCOPE OF THE REPORT
The ‘Sustained Release Ocular Drug Delivery Systems, 2015 – 2025 (2nd edition)’ report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases.

The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry.

The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts’ opinion reports

While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the ophthalmic drug delivery systemsmarket is headed in the short, mid and long term.

Chapter 3 provides a general introduction to the ophthalmic drug delivery market. We have discussed, in detail, the anatomy of the eye. The chapter also outlines details on different types of ocular drug delivery implants. In addition, several ocular indications, which are being targeted by sustained release implants, are also covered in this chapter.

Chapter 4 provides an overview of the ophthalmic drug delivery systems market with respect to the available marketed technologies and companies active in the field. We have provided a detailed pipeline of systems that are either marketed or are under clinical/ preclinical development. The chapter includes pipeline analysis by phase of development, system type, and indications targeted. It also covers the sustained release systems that are currently being evaluated by academic researchers and universities. In addition, we have also provided information on gene therapies that are being developed to provide a controlled treatment to several ocular indications.

Chapter 5 provides detailed profiles of 13 systems which are marketed and/ or arein late stages of clinical development (Phase II and Phase III). These profiles cover information on underlying technologies, development history, principal features (size of the implant, drug elution rate, life of the implant, related patents and intellectual property, nature of the insert) and current status of development. For each system, we have also estimated the future sales potential over the next ten years. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present different tracks of industry’s evolution.

Chapter 6 reviews the 13 leading companies which are active in the area of ophthalmology sustained release drug delivery technology. Each company profile includes information on the company overview, financial performance, marketed / pipeline systems, fundings, partnerships, and recent developments.

Chapter 7 provides information on several investment instances which have driven research in the area of sustained release ocular drug delivery systems. These investments are a testament to the growing interest of different stakeholders in this industry.

Chapter 8 covers details on the recent partnerships which have taken place in this industry. We have discussed the various partnerships models in existence and the most common forms of deals / agreements which have evolved over time.

Chapter 9 provides our analysis of the strengths, weaknesses, opportunities and threats in the ophthalmology drug delivery systems market, capturing the key elements likely to influence future growth.

Chapter 10 is a collection of transcripts based on our discussion with some of the leading players in the industry. Examples of companies interviewed include Neurotech Pharmaceuticals, Mati Therapeutics, On Demand Therapeutics and Euclid Systems.

Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 12 and 13 are appendices, which provide tabulated data and a list of companies mentioned in the report.

EXAMPLE HIGHLIGHTS
1. More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug.
2. Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien.
3. Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market.
4. DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma.
5. Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts.
6. The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics.

Table Of Contents

Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview
3.1. Introduction
3.2. Structure of the Eye

3.3. Ocular Drug Delivery Systems
3.3.1. Implantable Ocular Drug Delivery Systems
3.3.2. Particulate Drug Delivery Systems

3.4. Ocular Drug Delivery: Commonly Targeted Ophthalmic Disorders
3.4.1. Age-related Macular Degeneration
3.4.2. Cytomegalovirus Retinitis
3.4.3. Diabetic Retinopathy
3.4.4. Diabetic Macular Edema
3.4.5. Glaucoma
3.4.6. Ocular Infection
3.4.7. Uveitis
3.4.8. Retinal Vein Occlusion

4. MARKET OVERVIEW
4.1. Scope
4.2. Limited Marketed Ocular Systems for Sustained Drug Delivery
4.3. pSivida is the Key Technology Provider
4.4. Sustained Release Ocular Drug Delivery Systems: Pipeline Analysis
4.4.1. Distribution by Phase of Development
4.4.2. Distribution by Nature of Drug Delivery Systems
4.4.3. Distribution by Intraocular Placement of Drug Delivery Systems
4.4.4. Distribution by Indication Targeted
4.4.5. Novel Implants for Ocular Drug Delivery
4.4.6. Initial Focus on Anti-Inflammatory Drugs
4.4.7. Glaucoma: The Next Big Opportunity?
4.4.8. Universities' Interest in Ocular Sustained Drug Delivery Systems Market
4.5. Life Cycle Management Tool
4.6. Gene Therapy

5. PRODUCT PROFILES AND SALES FORECAST
5.1. Chapter Overview
5.2. Methodology and Assumptions
5.3. Overall Market Size and Forecast, 2015-2025

5.4. Retisert (Bausch and Lomb, Inc)
5.4.1. Product Overview
5.4.2. Development and Approval History
5.4.3. Product Specifications
5.4.4. Manufacturing of Retisert
5.4.5. Product Advantages
5.4.6. Associated Risks
5.4.7. Historical Sales
5.4.8. Sales Forecast, 2015-2025

5.5. Iluvien (Alimera Sciences)
5.5.1. Product Overview
5.5.2. Development and Approval History
5.5.3. Product Specifications
5.5.4. Manufacturing of Iluvien
5.5.5. Product Advantages
5.5.6. Associated Risks
5.5.7. Iluvien Contraindications
5.5.8. Historical Sales
5.5.9. CompetitiD10D39D12on
5.5.10. Opportunity for Iluvien
5.5.11. Sales Forecast, 2015-2025

5.6. Ozurdex (Allergan)
5.6.1. Product Overview
5.6.2. Development and Approval History
5.6.3. Product Specifications
5.6.4. Product Advantages
5.6.5. Associated Risks
5.6.6. Historical Sales and Reimbursement
5.6.7. Competition
5.6.8. Sales Forecast, 2015-2025

5.7. IBI-10090 (Icon Bioscience)
5.7.1. Product Specifications
5.7.2. Current Status of Development
5.7.3. Clinical Trial Results
5.7.4. Advantages
5.7.5. Competition
5.7.6. Sales Forecast, 2015-2025

5.8. OTX-DP (Ocular Therapeutix)
5.8.1. Product Specifications
5.8.2. Current Status of Development
5.8.3. Clinical Trial Results
5.8.4. Product Advantages
5.8.5. Competition
5.8.6. Sales Forecast, 2015-2025

5.9. Medidur (pSivida)
5.9.1. Product Specifications
5.9.2. Current Status of Development
5.9.3. Clinical Trial Results
5.9.4. Competition
5.9.5. Sales Forecast, 2015-2025

5.10. Bimatoprost Sustained Release Implant (Allergan)
5.10.1. Product Specifications
5.10.2. Current Status of Development
5.10.3. Clinical Trial Results
5.10.4. Product Advantages
5.10.5. Competition
5.10.6. Sales Forecast, 2015-2025

5.11. NT-501 (Neurotech Pharmaceuticals)
5.11.1. Product Specifications
5.11.2. Current Status of Development
5.11.3. Phase II Clinical Trial Results
5.11.4. Product Advantages
5.11.5. Sales Forecast, 2015-2025

5.12. Punctal Plug Delivery System (Mati Therapeutics)
5.12.1. Product Specifications
5.12.2. Current Status of Development
5.12.3. Clinical Trial Results
5.12.4. Product Advantages
5.12.5. Competition
5.12.6. Sales Forecast, 2015-2025

5.13. OTX-TP (Ocular Therapeutix)
5.13.1. Product Specifications
5.13.2. Current Status of Development
5.13.3. Clinical Trial Results
5.13.4. Product Advantages
5.13.5. Competition
5.13.6. Sales Forecast, 2015-2025

5.14. NT-503 (Neurotech Pharmaceuticals)
5.14.1. Product Specifications
5.14.2. Current Status of Development
5.14.3. Phase I Clinical Trial Results
5.14.4. Product Advantages
5.14.5. Sales Forecast, 2015-2025

5.15. Unnamed, Novadur (Allergan)
5.15.1. Product Specifications
5.15.2. Current Status of Development
5.15.3. Clinical Trial Results
5.15.4. Sales Forecast, 2015-2025

5.16. ProDex (Taiwan Liposome Company)
5.16.1. Product Specifications
5.16.2. Current Status of Development
5.16.3. Product/ Technology Advantages

5.17. Comparative Analysis of Sustained Release Ocular Drug Delivery Systems
5.17.1. Biodegradable Systems
5.17.2. Non-Biodegradable Systems

6. COMPANY PROFILES
6.1. Chapter Overview

6.2. pSivida
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Durasert and Tethadur Technology
6.2.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.2.5. Collaborations
6.2.6. Recent Developments

6.3. Allergan
6.3.1. Company Overview
6.3.2. Financial Performance
6.3.3. Novadur Technology
6.3.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.3.5. Collaborations
6.3.6. Recent Developments

6.4. Icon Bioscience
6.4.1. Company Overview
6.4.2. Funding
6.4.3. Verisome Technology
6.4.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.4.5. Recent Developments

6.5. Ocular Therapeutix
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Funding
6.5.4. Hydrogel Technology
6.5.5. Sustained Release Ocular Drug Delivery Systems Portfolio
6.5.6. Recent Developments

6.6. Neurotech Pharmaceuticals
6.6.1. Company Overview
6.6.2. Funding
6.6.3. Encapsulated Cell Technology
6.6.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.6.5. Collaborations

6.7. Santen Pharmaceutical
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. Ophthalmology: Leading Marketed Drugs
6.7.4. CHRONIJECT Microsphere Technology
6.7.5. Sustained Release Ocular Drug Delivery Systems Portfolio
6.7.6. Collaborations

6.8. Aciont Inc.
6.8.1. Company Overview
6.8.2. Funding
6.8.3. Visulex Technology
6.8.4. Sustained Release Ocular Drug Delivery Systems Portfolio

6.9. Envisia Therapeutics
6.9.1. Company Overview
6.9.2. Funding
6.9.3. Sustained Release Ocular Drug Delivery Technology
6.9.4. Sustained Release Ocular Drug Delivery Systems Portfolio

6.10. GrayBug
6.10.1. Company Overview
6.10.2. Funding
6.10.3. Sustained Release Ocular Drug Delivery Technology
6.10.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.10.5. GrayBug: In The News

6.11. Innocore Pharmaceuticals
6.11.1. Company Overview
6.11.2. Sustained Release Ocular Drug Delivery Technology
6.11.3. Sustained Release Ocular Drug Delivery Systems Portfolio
6.11.4. Collaborations

6.12. OHR Pharmaceuticals
6.12.1. Company Overview
6.12.2. Financial Performance
6.12.3. SKS Ocular Sustained Release Technology
6.12.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.12.5. Collaborations

6.13. PolyActiva
6.13.1. Company Overview
6.13.2. Funding
6.13.3. Sustained Release Ocular Drug Delivery Technology
6.13.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.13.5. Collaborations
6.14. TheraKine
6.14.1. Company Overview
6.14.2. Sustained Release Ocular Drug Delivery Technology
6.14.3. Sustained Release Ocular Drug Delivery Systems Portfolio
6.14.4. Collaborations

7. VENTURE CAPITAL SUPPORT
7.1. Chapter Overview
7.2. Instances of Investments / Grants in Sustained Release Ocular Drug Delivery Market
7.3. Growing Venture Capitalist Interest
7.4. Distribution of Funding Instances by Type of Funding
7.5. Distribution by Total Amount of Investment in a Category

8. RECENT PARTNERSHIPS
8.1. Chapter Overview
8.1.1. Partnership Models / Agreements
8.1.2. Collaborations Amongst Stakeholders are on a Rise
8.1.3. Product/ Technology Development, Acquisitions and Product/ Technology Licensing Are Preferred Modes of Collaboration
8.1.4. Most Active Companies in Sustained Release Ocular Drug Delivery Systems

9. SWOT ANALYSIS
9.1. Chapter Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats

10. INTERVIEW TRANSCRIPTS
10.1. Quinton Oswald, President and CEO, Neurotech Pharmaceuticals
10.2. Bob Butchofsky, Founder and CEO, Mati Therapeutics
10.3. John Santini, President and CEO, On Demand Therapeutics
10.4. Michael A Ross, Chief Executive Officer and Allan Kaplan, Chief Financial Officer, Euclid Systems
10.5. Other Anonymous Respondents

11. CONCLUSION
11.1. With A Huge Potential, Market Likely to Evolve Rapidly in Mid-Long Term
11.2. Ophthalmic Indications and Improved Patient Compliance Are Amongst the Several Growth Drivers
11.3. Key Emerging Technologies: Novel Methods for Efficient Drug Delivery
11.4. A Number of Opportunities Outweigh Existing Challenges
11.5. Concluding Remarks

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES

List of Figures
Figure 4.1 Ocular Drug Delivery Implants: Approval Timeline
Figure 4.2 Sustained Release Ocular Drug Delivery Systems: Distribution by Phase of Development
Figure 4.3 Sustained Release Ocular Drug Delivery Systems: Distribution by Nature of System
Figure 4.4 Sustained Release Ocular Drug Delivery Systems: Distribution by Site of Intraocular Placement
Figure 4.5 Sustained Release Ocular Drug Delivery Systems: Distribution by Target Indication
Figure 4.6 Sustained Release Ocular Drug Delivery Systems, University Research: Distribution by Target Indication
Figure 4.7 Lucentis Sales, 2010-2014 (USD Million)
Figure 4.8 Lumigan Sales, 2010-2014 (USD Million)
Figure 5.1 Overall Sales Forecast, Short-Mid Term (2014 - 2020), USD Million (Base Scenario)
Figure 5.2 Overall Sales Forecast, Mid- Long term (2020 - 2025), USD Million (Base Scenario)
Figure 5.3 Retisert Sales, 2010 - 2014 (USD Million)
Figure 5.4 Retisert Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.5 Retisert Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.6 Iluvien Sales, 2013-2014 (USD Million)
Figure 5.7 IVT Treated DME: US Market Share by Leading Drugs (%)
Figure 5.8 Iluvien Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.9 Iluvien Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.10 Ozurdex Development Timeline
Figure 5.11 Ozurdex Sales, 2010 - 2014 (USD Million)
Figure 5.12 Ozurdex Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.13 Ozurdex Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.14 IBI-10090 Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.15 IBI-10090 Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.16 OTX-DP Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.17 Retisert, Iluvien, Ozurdex and Medidur: Percentage Share of Patients Reported to Have Developed IOP
Figure 5.18 Medidur Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.19 Bimatoprost Sustained Release Implant Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.20 NT-501 Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.21 PPDS Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.22 OTX-TP Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.23 NT-503 Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.24 Unnamed (Novadur) Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.25 Biodegradable Sustained Release Ocular DDS: Comparative Analysis
Figure 5.26 Non-Biodegradable Sustained Release Ocular DDS: Comparative Analysis
Figure 6.1 pSivida Revenues, 2012-Q3 2015 (USD ‘000)
Figure 6.2 Allergan Revenues, 2010-2014 (USD Million)
Figure 6.3 Allergan Revenues: Distribution by Business Segment, 2012-2014 (USD Million)
Figure 6.4 Allergan Specialty Pharmaceuticals Revenues: Distribution by Therapeutic Areas, 2014 (USD Million)
Figure 6.5 Allergan Revenues: Distribution by Sub-Segments of Medical Devices, 2014 (USD Million)
Figure 6.6 Allergan: Sales of Leading Marketed Ophthalmic Drugs (USD Million), 2013-2014
Figure 6.7 Icon Bioscience: Milestone Chart
Figure 6.8 Ocular Therapeutix Revenues, 2014 (USD'000)
Figure 6.9 Neurotech Pharmaceuticals: Milestone Chart
Figure 6.10 Santen Revenues: 2009-Q3 2015 (JPY Million)
Figure 6.11 Santen Revenues: Distribution by Business Segments, 2012-2014 (JPY Million)
Figure 6.12 Santen Revenues: Distribution by Sub-Segments of Pharmaceutical Business, 2014 (JPY Million)
Figure 6.13 Santen Revenues: Distribution by Sub-Segments of Other Businesses, 2014 (JPY Million)
Figure 6.14 OHR Pharmaceuticals: Operating Expenses, 2010- Q1 2015 (USD ‘000)
Figure 7.1 Sustained Release Ocular DDS Funding Instances: Cumulative Investments by Year, 2003-2015
Figure 7.2 Sustained Release Ocular DDS Funding Instances: Distribution by Categories
Figure 7.3 Sustained Release Ocular DDS Funding Instances: Distribution by Amount Invested in a Category (USD Million)
Figure 8.1 Sustained Release Ocular DDS Partnerships: Cumulative Partnerships by Year, 2001-2014
Figure 8.2 Sustained Release Ocular DDS Partnerships: Distribution by Type of Partnership
Figure 8.3 Sustained Release Ocular DDS Partnerships: Major Stakeholders
Figure 11.1 Ocular Drug Delivery Implants: Market Landscape And Growth Drivers
Figure 11.2 Sustained Release Ocular DDS Market, 2015, 2020, 2025 (USD Million)?

List of Tables
Table 3.1 Eye: Description of Tissue Layers
Table 4.1 Availability of Ocular Drug Delivery Implants in the US and Europe
Table 4.2 Sustained Release Ocular Drug Delivery Systems: Pipeline
Table 4.3 Sustained Release Ocular Drug Delivery Systems: Research Projects at Universities
Table 4.4 Gene Therapies under Development for Ocular Diseases
Table 5.1 Current Development Phase and Expected Launch Year of Drug Delivery Systems (Phase II and Higher)
Table 5.2 Comparison of Iluvien with Currently Available Drugs for DME
Table 5.3 Vision Loss Associated with DME, Number of Patients in the US and Major EU Countries, 2012
Table 5.4 Market Potential for Iluvien in the US
Table 5.5 Approval of Ozurdex in Different Geographies
Table 5.6 IBI-10090: Completed Clinical Trials
Table 5.7 IBI-10090: Clinical Trial Results
Table 5.8 IBI-10090 and Marketed Topicals: Comparison of Anterior Chamber Cell Count
Table 5.9 IBI10090: Competitive Landscape
Table 5.10 OTX-DP: Ongoing Clinical Trials
Table 5.11 OTX-DP: Clinical Trial Results
Table 5.12 Medidur: Status of Development
Table 5.13 Medidur: Competitive Landscape
Table 5.14 Medidur and Available Drugs for Posterior Uveitis: Comparative Analysis
Table 5.15 Bimatoprost Implant: Patents
Table 5.16 NT-501: Ongoing Clinical Trials
Table 5.17 PPDS: Patents
Table 5.18 OTX-TP: Clinical Trials
Table 5.19 OTX-TP: Efficacy Results
Table 5.20 NT-503: Key Features
Table 5.21 NT503: Clinical Trial Result
Table 5.22 Brimonidine Implant: Patents
Table 5.23 Unnamed (Novadur): Clinical Trials
Table 5.24 Biodegradable Sustained Release Ocular DDS: Comparative Analysis
Table 5.25 Non-Biodegradable Sustained Release Ocular DDS: Comparative Analysis
Table 6.1 pSivida: Sustained Release Ocular DDS Pipeline
Table 6.2 pSivida: Revenues Received from Alimera Sciences (2009-2013), USD Million
Table 6.3 pSivida: Revenues Received from Restated Pfizer Agreement (2009-2013), USD Million
Table 6.4 Marketing Authorization Approvals: Iluvien (2014-2015)
Table 6.5 Allergan: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.6 Icon Bioscience: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.7 Ocular Therapeutix: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.8 Neurotech Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.9 NT-501: Orphan Drug and Fast Track Designations
Table 6.10 Neurotech: Research Collaborations
Table 6.11 Santen: Pipeline of Ophthalmology Drugs/ Systems
Table 6.12 Aciont Inc: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.13 Envisia Therapeutics: Company Overview
Table 6.14 Envisia Therapeutics: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.15 GrayBug: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.16 GrayBug: In The News
Table 6.17 Innocore Pharmaceuticals: Company Overview
Table 6.18 Innocore Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.19 OHR Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.20 PolyActiva: Company Overview
Table 6.21 PolyActiva: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.22 TheraKine: Company Overview
Table 6.23 TheraKine: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 7.1 List of Funding Rounds / Grants and Investors Involved
Table 8.1 Sustained Release Ocular Drug Delivery Systems: List of Partnerships
Table 9.1 Sustained Release Ocular Drug Delivery Systems: SWOT Analysis
Table 9.2 Development of Sustained Release Ocular Systems: Example Venture Capital Funding Instances
Table 12.1 Sustained Release Ocular Drug Delivery Systems: Distribution by Phase of Development
Table 12.2 Sustained Release Ocular Drug Delivery Systems: Distribution by Nature of System
Table 12.3 Sustained Release Ocular Drug Delivery Systems: Distribution by Site of Intraocular Placement
Table 12.4 Sustained Release Ocular Drug Delivery Systems: Distribution by Target Indication
Table 12.5 Sustained Release Ocular Drug Delivery Systems, University Research: Distribution by Target Indication
Table 12.8 Overall Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Base Scenario)
Table 12.9 Overall Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
Table 12.10 Overall Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Conservative Scenario)
Table 12.11 Overall Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
Table 12.12 Overall Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Optimistic Scenario)
Table 12.13 Overall Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
Table 12.14 Retisert Sales, 2010-2014 (USD Million)
Table 12.15 Retisert Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Base Scenario)
Table 12.16 Retisert Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
Table 12.17 Retisert Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Conservative Scenario)
Table 12.18 Retisert Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
Table 12.19 Retisert Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Optimistic Scenario)
Table 12.20 Retisert Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
Table 12.21 Iluvien Sales, 2013-2014 (USD Million)
Table 12.22 IVT Treated DME: US Market Share by Leading Drugs (%)
Table 12.23 Iluvien Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Base Scenario)
Table 12.24 Iluvien Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
Table 12.25 Iluvien Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Conservative Scenario)
Table 12.26 Iluvien Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
Table 12.27 Iluvien Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Optimistic Scenario)
Table 12.28 Iluvien Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
Table 12.30 Ozurdex Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Base Scenario)
Table 12.31 Ozurdex Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
Table 12.32 Ozurdex Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Conservative Scenario)
Table 12.33 Ozurdex Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
Table 12.34 Ozurdex Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Optimistic Scenario)
Table 12.35 Ozurdex Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
Table 12.36 IBI-10090 Sales Forecast, Short-Mid Term (2016 - 2020), USD Million (Base Scenario)
Table 12.37 IBI-10090 Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
Table 12.38 IBI-10090 Sales Forecast, Short-Mid Term (2016 - 2020), USD Million (Conservative Scenario)
Table 12.39 IBI-10090 Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
Table 12.40 IBI-10090 Sales Forecast, Short-Mid Term (2016 - 2020), USD Million (Optimistic Scenario)
Table 12.41 IBI-10090 Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
Table 12.42 OTX-DP Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
Table 12.43 OTX-DP Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
Table 12.44 OTX-DP Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
Table 12.45 Retisert, Iluvien, Ozurdex and Medidur: % Share of Patients Reported to Have Developed IOP
Table 12.46 Medidur Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
Table 12.47 Medidur Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
Table 12.48 Medidur Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
Table 12.49 Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
Table 12.50 Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
Table 12.51 Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
Table 12.52 NT-501 Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
Table 12.53 NT-501 Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
Table 12.54 NT-501 Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
Table 12.55 PPDS Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
Table 12.56 PPDS Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
Table 12.57 PPDS Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
Table 12.58 OTX-TP Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
Table 12.59 OTX-TP Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
Table 12.60 OTX-TP Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
Table 12.61 NT-503 Sales Forecast, Mid-Long Term (2021 - 2025), USD Million (Base Scenario)
Table 12.62 NT-503 Sales Forecast, Mid-Long Term (2021 - 2025), USD Million (Conservative Scenario)
Table 12.63 NT-503 Sales Forecast, Mid-Long Term (2021 - 2025), USD Million (Optimistic Scenario)
Table 12.64 Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 - 2025), USD Million (Base Scenario)
Table 12.65 Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 - 2025), USD Million (Conservative Scenario)
Table 12.66 Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 - 2025), USD Million (Optimistic Scenario)
Table 12.67 pSivida Revenues, 2012- Q3 2015 (USD'000)
Table 12.68 Allergan Revenues, 2010- 2014 (USD Million)
Table 12.69 Allergan Revenues: Distribution by Business Segment, 2012-2014 (USD Million)
Table 12.70 Allergan Specialty Pharmaceuticals Revenues: Distribution by Therapeutic Areas, 2014 (USD Million)
Table 12.71 Allergan Revenues: Distribution by Sub Segments of Medical Devices, 2014 (USD Million)
Table 12.72 Allergan: Sales for Leading Marketed Ophthalmic Drugs, 2013-2014 (USD Million)
Table 12.73 Ocular Therapeutix Revenues, 2014 (USD' 000)
Table 12.74 Santen Revenues, 2009- Q3 2015 (JPY Million)
Table 12.75 Santen Revenues: Distribution by Business Segments, 2012-2014 (JPY Million)
Table 12.76 Santen Revenues: Distribution by Sub-Segments of Pharmaceutical Business, 2013-2014 (JPY Million)
Table 12.77 Santen Revenues: Distribution by Sub-Segments of Other Businesses, 2013-2014 (JPY Million)
Table 12.78 OHR Pharmaceuticals: Operating Expenses, 2010-Q1 2015 (USD'000)
Table 12.79 Sustained Release Ocular DDS Funding Instances: Cumulative Investments by Year, 2003-2015
Table 12.80 Sustained Release Ocular DDS Funding Instances: Distribution by Categories
Table 12.81 Sustained Release Ocular DDS Funding Instances: Distribution by Amount Invested In a Category (USD Million)
Table 12.82 Sustained Release Ocular DDS: Cumulative Partnerships by Year, 2001-2014
Table 12.83 Sustained Release Ocular DDS Partnerships: Distribution by Type of Partnership
Table 12.84 Sustained Release Ocular DDS Partnerships: Major Stakeholders

Companies Mentioned
"1. 3i Plc
2. AbbVie
3. Abell Foundation
4. Aciont, Inc.
5. Actavis Plc
6. Aerie Pharmaceutical
7. Ain Shams University, Cairo, Egypt
8. Alcon
9. Alimera Sciences
10. Allergan
11. Alliance Medical Products Inc
12. Alpha Associates
13. Amgen Inc.
14. Amorphex Therapeutics
15. Apax Partners
16. Ascension Health Ventures
17. Atlas Venture
18. Auritec Pharmaceuticals
19. Avida Group
20. Bausch and Lomb
21. Baxter Venture
22. Bayer Healthcare
23. BCN Peptides
24. Ben Venue Laboratories
25. BioLight Israeli Life Sciences Investments Ltd.
26. Brandon Biosciences
27. Brecon Pharmaceuticals Ltd
28. Brown Advisory
29. Burrill and Company
30. Byron Chemical Company
31. Caja Navarra
32. Canaan Partners
33. Can-Fite BioPharma
34. Catania University, Catania, Italy
35. Centre for Eye Research Australia (CERA)
36. Chang Gung University
37. Chiron Vision Corporation
38. Chongqing Medical University
39. Clave Mayor
40. Control Delivery Systems Inc.
41. Corporación CAN
42. Cullen Eye Institute, Baylor College of Medicine
43. Domain Associates
44. Duke Reading Center
45. Duke University Medical Center
46. Economic Committee for Health Products
47. Enigma Therapeutics
48. Envisia Therapeutics
49. Ergo Equity
50. ESBATech (a Biomedical Research Unit of Alcon)
51. Euclid Systems
52. EVS Glaucoma Therapeutics
53. FARMABIOS SpA
54. Federal University of Minas Gerais
55. Flextronics International Ltd
56. ForSight Labs
57. Genentech
58. GIMV
59. GP Pharm
60. GrayBug
61. Hatteras Venture Partners
62. Health Ventures
63. Hercules Technology Growth Capital
64. Hospital Research Center, Linkoping University
65. Icon Bioscience
66. IIT Roorkee
67. Innocore
68. Institute for Advanced Chemistry of Catalonia
69. Institute of Nanoscience and Nanotechnology, Barcelona
70. Intersouth Partners
71. InterWest Partners
72. Intrinsiq
73. Inveready
74. Johns Hopkins University School of Medicine
75. Kyoto University, Faculty of Medicine
76. le Venture Partners
77. Lowy Medical Research Institute (LMRI)
78. Maryland Biotechnology Center
79. Maryland Venture
80. Mati Therapeutics
81. Mayflower
82. Medicines and Healthcare products Regulatory Agency
83. Melbourne University
84. Memorial Sloan Kettering Cancer Center
85. Merlin Biosciences
86. MIT, Boston
87. Monash University
88. Morningside Group
89. Nanomi
90. Nanyang Technological University, Singapore
91. National Eye Institute
92. National Institute for Health and Care Excellence (NICE)
93. National Institutes of Health Clinical Center
94. National Tsing Hua University
95. Navarra Civic Banking
96. Neurotech Pharma
97. New Enterprise Associates
98. Nexus Medical Partners
99. Nishi Eye Hospital, Osaka, Japan
100. Novagali Pharma
101. Novartis
102. Nuclear Magnetic Resonance Unit, Barcelona
103. Oakwood Laboratories
104. OctoPlus
105. Ocular Therapeutix
106. Oculex Pharmaceuticals
107. OHR Pharmaceuticals
108. On Demand Therapeutics
109. OncoSil Medical
110. Ora Inc.
111. Pappas Ventures
112. Pfizer
113. Polaris Ventures
114. Polyactiva
115. Pound Capital
116. ProRetina Therapeutics
117. pSivida Corp
118. QLT Inc.
119. Rainbow Biosciences
120. Real Fleece FCR
121. Regeneron
122. Replenish, Inc.
123. Roche
124. Sanofi
125. Santen
126. Sanwa Kagaku Kenkyusho
127. Sao Paulo State University
128. School of Pharmacy, West Virginia University
129. Signet Healthcare Partners
130. Singapore Eye Research Institute
131. SKS Ocular LLC
132. Sodena (Navarra Development Society )
133. Sparta LLC
134. Specialized Therapeutics
135. SV Life Sciences
136. Taiwan Liposome Company
137. The EMMES Corporation
138. TheraKine
139. Tulane University Medical Center
140. United Centers for Advanced Research and Translational Medicine (ART)
141. University of Barcelona
142. University of California
143. University of Cincinnati
144. University of Colorado
145. University of Florida
146. University of Miami
147. University of Nebraska
148. University of Ottawa, Ottawa
149. University of Pittsburgh
150. University of Porto
151. University of Waterloo
152. Valeant Pharmaceuticals
153. Venrock
154. Versant Ventures
155. Wakefield Group
156. Wayne State University
157. West LB
158. Wilmer Eye Institute at Johns Hopkins University
159. World Health Organization
160. XOMA
161. Yuwa capital"


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.